We are live on ! Find out more
SCM

Silverarc Capital Management Portfolio holdings

AUM $962M
1-Year Est. Return 524.64%
This Fund
S&P 500
This Quarter Est. Return
+33.87%
1 Year Est. Return
+524.64%
3 Year Est. Return
+2,765.44%
5 Year Est. Return
+10,523.08%
10 Year Est. Return
–
AUM
$336M
AUM Growth
+$6.15M
Cap. Flow
-$5.31M
Cap. Flow %
-1.58%
Top 10 Hldgs %
38.74%
Holding
96
New
16
Increased
28
Reduced
16
Closed
29

Top Buys

Rank Stock Value
1
NUVL
Nuvalent
NUVL
+$11.9M
2
SNY icon
Sanofi
SNY
+$10.8M
3
MDT icon
Medtronic
MDT
+$10.3M
4
RCKT icon
Rocket Pharmaceuticals
RCKT
+$8.45M
5
CLDX icon
Celldex Therapeutics
CLDX
+$7.27M

Top Sells

Rank Stock Value
1
IMGN
Immunogen Inc
IMGN
+$20.7M
2
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$11.2M
3
SLNO
Soleno Therapeutics
SLNO
+$8.43M
4
KRYS icon
Krystal Biotech
KRYS
+$8.3M
5
ITCI
Intra-Cellular Therapies Inc.
ITCI
+$7.41M

Sector Composition

Rank Sector Weight
1 Healthcare 96.5%
2 Miscellaneous 3.5%
3 Consumer Staples 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MRUS
1
DELISTED
Merus
MRUS
$17.8M 5.28%
645,581
+145,581
+29% +$3.4M
MRSN
2
DELISTED
Mersana Therapeutics
MRSN
$14.9M 4.43%
256,805
+56,805
+28% +$2.29M
MORF
3
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$14.4M 4.3%
500,042
-90,787
-15% -$2.16M
NUVL
4
DELISTED
Nuvalent
NUVL
$14.2M 4.23%
+193,000
New +$11.9M
PSTX
5
DELISTED
Poseida Therapeutics, Inc. Common Stock
PSTX
$12.5M 3.71%
3,705,779
+137,794
+4% +$355K
MGNX icon
6
MacroGenics
MGNX
$263M
$12.1M 3.6%
1,258,641
-5,517
-0.4% -$38.1K
RCKT icon
7
Rocket Pharmaceuticals
RCKT
$424M
$11.5M 3.41%
+382,672
New +$8.45M
MDT icon
8
Medtronic
MDT
$117B
$11.1M 3.31%
+135,000
New +$10.3M
SNY icon
9
Sanofi
SNY
$107B
$10.9M 3.26%
+220,000
New +$10.8M
ORIC icon
10
Oric Pharmaceuticals
ORIC
$1.37B
$10.8M 3.2%
1,170,000
+46,655
+4% +$337K
CLDX icon
11
Celldex Therapeutics
CLDX
$3.07B
$9.8M 2.92%
+247,215
New +$7.27M
MRTX
12
CALL
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$8.81M 2.62%
150,000
– –
OLMA icon
13
Olema Pharmaceuticals
OLMA
$899M
$8.05M 2.4%
573,830
+166,029
+41% +$2.23M
RYTM icon
14
Rhythm Pharmaceuticals
RYTM
$7.38B
$8.01M 2.38%
174,248
-86,289
-33% -$2.72M
URGN icon
15
UroGen Pharma
URGN
$2.13B
$7.88M 2.35%
525,404
+16,521
+3% +$214K
XENE icon
16
Xenon Pharmaceuticals
XENE
$5.81B
$7.52M 2.24%
163,168
+109,172
+202% +$3.86M
VCYT icon
17
Veracyte
VCYT
$3.48B
$6.81M 2.03%
247,723
+8,152
+3% +$197K
PRAX icon
18
Praxis Precision Medicines
PRAX
$9.63B
$6.32M 1.88%
283,841
+9,313
+3% +$168K
AKRO
19
DELISTED
Akero Therapeutics
AKRO
$5.82M 1.73%
249,254
+217,918
+695% +$4.3M
PLRX icon
20
Pliant Therapeutics
PLRX
$68.7M
$5.77M 1.72%
318,524
+68,115
+27% +$1.04M
ITCI
21
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$5.73M 1.71%
80,000
-128,730
-62% -$7.41M
COGT icon
22
Cogent Biosciences
COGT
$6.02B
$5.68M 1.69%
966,748
+315,376
+48% +$2.42M
ALPN
23
DELISTED
Alpine Immune Sciences Inc
ALPN
$5.68M 1.69%
+297,789
New +$4.14M
GOSS icon
24
Gossamer Bio
GOSS
$83.2M
$5.59M 1.67%
6,130,268
– –
ISRG icon
25
Intuitive Surgical
ISRG
$132B
$5.33M 1.59%
+15,808
New +$4.71M
1
2 3 4

Similar funds

LGP
Leonard Green & Partners Los Angeles, California $962M AUM 35.11% 1-Year Est. Return
PL
Parthenon LLC Louisville, Kentucky $962M AUM 27.46% 1-Year Est. Return
LAM
L2 Asset Management Wayland, Massachusetts $963M AUM 38.06% 1-Year Est. Return
ACP
Aviance Capital Partners Naples, Florida $963M AUM 32.56% 1-Year Est. Return
GIG
Goodnow Investment Group Darien, Connecticut $964M AUM 2.51% 1-Year Est. Return
AAP
Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return
BEAM
Baker Ellis Asset Management Vancouver, Washington $964M AUM 39.24% 1-Year Est. Return
RAM
Ramirez Asset Management New York $960M AUM 30.25% 1-Year Est. Return

Silverarc Capital Management's Q4 2023 Portfolio in Review

As of Q4 2023, Silverarc Capital Management held 96 positions worth $336M, up 1.9% from $330M the previous quarter. Its ten largest holdings account for 39% of the portfolio.

Silverarc Capital Management's Q4 2023 filing shows 16 new, 28 increased, 16 reduced and 29 closed positions. Its largest new stake was Nuvalent: 193,000 shares worth $14.2M. The largest sale was Immunogen Inc, an estimated $20.7M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 81% a quarter earlier, followed by Miscellaneous and Consumer Staples.

  • Silverarc Capital Management's largest Q4 2023 buy was Nuvalent: 193,000 shares worth $14.2M.
  • Silverarc Capital Management added most to Akero Therapeutics in Q4 2023, an estimated $4.3M increase.
  • Silverarc Capital Management's biggest Q4 2023 reduction was Soleno Therapeutics, cutting an estimated $8.43M.
  • Silverarc Capital Management fully exited Immunogen Inc in Q4 2023, selling an estimated $20.7M.
  • Silverarc Capital Management's ten largest holdings make up 39% of its $336M portfolio in Q4 2023.
  • Silverarc Capital Management opened 16 new positions and closed 29 in Q4 2023.
  • Silverarc Capital Management's portfolio value rose 1.9% quarter-over-quarter to $336M.

Based on Silverarc Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.